Aldeyra Therapeutics (ALDX)
Develops RASP modulators and ophthalmology candidates for immune-mediated diseases.
$1.35
vs last close−0.04 (−3.23%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 60.56% | 36.53M shares | |
|---|---|---|---|
| 114 holders · as of Jun 30, 2026 | |||
| Insiders | 3.56% | 2.15M shares | |
| 5 holders · as of Jun 5, 2026 | |||
| Other | 35.88% | 21.65M shares | |
| remainder | |||
60.33M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
13F, as of Jun 30, 2026
114 holders · 36.53M shares · 19 new positions · 49 increased · 44 reduced · 39 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Knoll Capital Management, LLC | 5.48M | 9.08% | 0 | Sep 10, 2026 |
| AQR Capital Management LLC | 3.75M | 6.22% | +921.7K | Aug 14, 2026 |
| Kingdon Capital Management, L.L.C. | 2.65M | 4.40% | +500.0K | Aug 14, 2026 |
| Vanguard Capital Management LLC | 2.36M | 3.92% | −1.9K | Aug 13, 2026 |
| D. E. Shaw & Co., Inc. | 1.94M | 3.22% | +536.3K | Aug 14, 2026 |
| Marshall Wace, LLP | 1.51M | 2.50% | +1.38M | Aug 13, 2026 |
| 683 Capital Management, LLC | 1.45M | 2.40% | −50.0K | Aug 14, 2026 |
| Jane Street Group, LLC | 1.38M | 2.28% | +406.2K | Aug 14, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| AQR Capital Management, LLC | 6.22% | 3.75M | 13G | Aug 12, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Jun 3, 2026 | Todd C. Bradydirector, officer: President and CEO | Purchase | 250,000 | $1.67 | 1,721,298 |
| Mar 19, 2026 | Richard Douglasdirector | Purchase | 70,000 | $1.40 | 195,000 |
| Mar 18, 2026 | Michael Alfieriofficer: Principal Financial Officer | Purchase | 5,000 | $1.42 | 7,500 |
House and Senate disclosures
Not reported.